Radiopharmaceutical Manufacturing Readiness

Radiopharmaceutical Manufacturing Readiness means bringing the applicable manufacturing framework, usable materials, suitable equipment, production instructions, testing capacity and decision-makers together before committing to a run. A production slot alone is not readiness. The useful planning question is whether the complete chain can finish without assuming that an unavailable resource, pending result or missing authorization will somehow resolve itself.

Law — § 212.5 provides this guide’s boundary. Part 212 applies only to the production, quality assurance, holding and distribution of PET drugs. Human drugs outside the PET definition must be manufactured under the current good manufacturing practice requirements in Parts 210 and 211. This is a framework orientation, not a claim that all radiopharmaceutical manufacturing follows one protocol.

The investigational alternative concerns human-use PET drugs produced under an IND in accordance with Part 312, and PET drugs produced with RDRC approval in accordance with Part 361. The incorporated reference is Chapter 823 in USP 32/NF 27, dated May 1, 2009—not an unspecified current USP chapter. Only the alternative stated in § 212.5 is described here; the chapter itself is not interpreted.

Reading convention: paragraphs identified as law summarize the supplied Part 212 text. Planning recommendations and fictional examples are site-designed practice, not additional legal requirements. Scientific references are nonbinding technical context. For the detailed manufacturing foundation, use the PET drug CGMP guide; for a shorter orientation, use the 21 CFR 212 definition.

Planning practice — create a run request that identifies the product, intended batch, receiving facility, requested dispatch time, time zone and assumptions still awaiting confirmation. Keep requested, feasible, committed and actual times in separate fields. A request expresses demand; a feasible time reflects the currently available resources and dependencies. Neither establishes that a future batch will meet specifications.

Avoid a single green status for the whole run. A cassette may be available while a precursor lot remains pending. Production may be complete while laboratory data await review. A reviewer may have finished examining a record without authorizing final release. These differences matter whenever the next team is deciding whether to prepare, wait, investigate or hand over.

Law — § 212.1 distinguishes material release from final release. Material release permits specified materials to be used in PET drug production; final release is the authoritative product-use decision. Under § 212.70(d), the designated qualified individual authorizes final release by dated signature after the required determination and review, except within the conditional-release provisions.

Planning practice — attach an owner, evidence reference and next action to each unresolved state. “Pending QC” is too broad if the real dependency is an instrument returning from maintenance, a missing calculation or a reviewer who is unavailable until later. Use text labels as well as any visual indicators so the handover remains understandable without interpreting colors.

Law — § 212.40(c) requires unique identification and testing or examination of incoming component, container and closure lots. Incoming lots must be designated quarantined, accepted or rejected. A lot that does not meet specifications, including an applicable expiration date, or has not received material release must not be used in PET drug production. Physical presence is therefore not evidence of usability.

Planning practice — check precursor, reagent, consumable and container-closure availability at the lot level under the applicable site procedures. For each item, distinguish quantity physically present, material status, existing commitments and the quantity available for a new reservation. Do not treat a delivery confirmation, supplier document awaiting assessment or stockroom count as a substitute for the relevant disposition decision.

Fictional cassette reconciliation exercise

The following site-designed exercise uses cassette units tracked across distinct disposition groups. The accepted group is assumed to have received the necessary material release. All units remain on site except the two later consumed by Run A. The quantities are invented and do not prescribe a manufacturing bill of materials.

The independent whole-stock check is 20 received minus 2 consumed equals 18 physically remaining: 13 accepted, 3 quarantined and 2 rejected. That check does not make the five nonaccepted units usable. If Run B is cancelled, a deliberate reservation change can return its two units to the free balance, provided their accepted status remains applicable; cancellation itself is not a new material-release decision.

Law — § 212.40(e) requires a receipt record for each shipment of each component, container and closure lot, including identity, quantity, supplier and supplier lot, receipt date, testing results, rejected-material disposition and applicable expiration. Planning practice adds the reservation ledger and links its transactions to those lot records, rather than overwriting the original receipt or disposition history.

Law — § 212.30(b) requires procedures and documented activities to ensure relevant equipment is clean, suitable, properly installed, maintained and capable of repeatedly producing valid results. For laboratory equipment, § 212.60(e) requires suitability and valid-result capability; § 212.60(f) requires documented routine calibration, inspection, checking and maintenance under written procedures.

Planning practice — translate these requirements into dated availability, not a static equipment list. Examine the applicable qualification or suitability evidence, configuration, calibration status, maintenance work and any restrictions under site procedures. “Installed” does not mean available for this run. “Available today” does not establish that the equipment remains available throughout the proposed production or testing interval.

Law — the production area and all equipment in it must be checked for cleanliness and suitability immediately before use, with a record kept, under § 212.50(d). A readiness meeting on the previous afternoon cannot satisfy that timing by itself.

Planning practice — reserve setup, changeover, checks and maintenance recovery explicitly. A maintenance end time is initially an estimate; availability changes only when the applicable work and return-to-use evidence support it. If a replacement instrument or production unit is proposed, assess its suitability and the applicable procedures rather than assuming a free asset can substitute. Apply the same discipline to staff cover: a name on an escalation list is not a confirmed reviewer appointment.

Law — § 212.50 requires written production and process controls, master records documenting all production steps, and a unique batch production and control record each time a batch is produced. The batch record includes major steps from the approved appropriate master, component identification and quantities, production dates and critical times, equipment, test results, labeling, personnel entries and investigation results.

Planning practice — link each proposed run to the applicable approved master and revision before estimating duration. Use that process to identify materials, equipment and handoffs. The planning calendar should reference the batch record once created, but should not become an alternative set of production instructions. A shorter calendar bar cannot silently change a sampling step, acceptance criterion or approved process.

A practical forward-planning rule is to start each activity no earlier than both its predecessor’s completion and the resource’s next usable interval. Availability must cover the whole activity, not merely its first minute. Apply the rule separately to production equipment, the QC work center, the reviewer and the packing or handover station.

Backward planning from a requested dispatch time can reveal what would have to happen, but cannot create capacity. Compare that backward chain with the actual calendars, then retain a feasible forward plan. Label any unconfirmed duration or resource as an assumption. Allowance for variability should come from site knowledge of the process, not from an arbitrary buffer presented as a regulatory standard.

Assume one production resource, one shared QC work center, one reviewer, one packing station and one handover position. Different work centers have distinct personnel, so production can overlap QC without double-booking a person. The production changeover and required checks are assumed to fit the reserved five-minute gap; that duration is not a general recommendation. Run A’s immediate pre-use check is assumed to be completed just before its start.

For this exercise only, “dispatch complete” means handover has finished and the shipment leaves at that time. Run B requests dispatch complete by 10:15. QC includes the applicable pre-release testing work assumed for the exercise; sterility follow-up is tracked separately. Review slots reserve capacity but do not guarantee a favorable decision.

Check the arithmetic: each run has 45 minutes of production, 30 of QC, 10 of review, 10 of packing and 10 of handover—105 minutes altogether. Run A therefore spans 08:00–09:45; Run B spans 08:50–10:35. Across the QC calendar, 30 minutes for A plus 20 minutes of maintenance plus 30 minutes for B fill 08:45–10:05 without concurrent use.

Run B’s 10:15 request is infeasible by 20 minutes: 10:35 minus 10:15 equals 20. At the requested dispatch time, only its planned review has finished; packing and handover still require 20 minutes. Moving its QC block earlier would conflict with both its production completion and the maintenance interval. An idle reviewer earlier in the morning does not remove those dependencies.

The planning response is to communicate the feasible 10:35 completion, or review a genuinely different resource arrangement and rebuild the entire chain. Do not erase maintenance, shorten testing, assume a signature or invent overtime. Any alternative remains provisional until its resources, procedures and downstream handoffs have been checked.

Nonbinding technical context — the IAEA practical decay summary explains why an activity result needs a reference time. The supplied LNHB fluorine-18 evaluation recommends a half-life of 109.734 minutes. These scientific references do not authorize manufacturing release or determine a dispatch commitment.

Fictional arithmetic exercise — consider a sealed bulk sample containing F-18, separate from Runs A and B. Its known activity is assumed to be exactly 1,000 MBq at 09:00 UTC on 19 October 2026. Calculate the activity at 10:00 UTC on the same date using simple decay, with no replenishment or parent ingrowth and with uncertainty omitted solely for this classroom calculation.

1. Elapsed time: 10:00 − 09:00 = 60 minutes.
2. Forward equation: A(10:00) = 1,000 × 2^(−60 / 109.734) MBq.
3. The decay factor is approximately 0.68455, giving approximately 684.55 MBq at 10:00.
4. Inverse check: multiply the unrounded forward result by 2^(60 / 109.734). The result returns to 1,000 MBq at 09:00.
5. Using the displayed, rounded 684.55 MBq instead returns approximately 1,000 MBq; rounding prevents an exact displayed-value identity.

The check illustrates why quantity, unit, reference date, reference time and time zone belong together. Replacing 09:00 with 10:00 without changing the value would describe a different assertion. Equally, applying the inverse factor while intending to move forward in time would increase the value in this simple unsupported-decay model and expose a direction error.

For terminology and reference-time distinctions, see decay correction. Keep that calculation topic separate from the finite-resource and authorization questions in the run plan.

Law — § 212.70(c) requires an appropriate laboratory determination before final release that each batch, or each sub-batch where applicable, conforms to specifications except for sterility. Under § 212.70(d), associated laboratory data and documentation are reviewed and demonstrate conformity except for sterility, and a designated qualified individual authorizes final release by dated signature, subject to the narrow conditional-release provision. Scheduling urgency does not change these requirements.

Planning practice — carry pending sterility work, and any applicable conditional-release follow-up, as explicit tasks with owners, sample references and linked receiving facilities. Do not merge “sterility pending” with “test omitted because of malfunction.” This section identifies the planning interfaces; the PET CGMP foundation provides the broader manufacturing context rather than this calendar serving as a release procedure.

Planning practice — when a milestone slips, preserve the original commitment and add a revised forecast with its reason. Identify the first unmet dependency, which resources are affected, and who can resolve it. Recalculate downstream intervals rather than moving only the dispatch label. A revised finish time is useful only if production, QC, review, packing and handover still fit their actual calendars.

Law — § 212.71 requires rejection of nonconforming product, procedures for identification and segregation to prevent mix-ups, and investigation of the causes. The investigation and disposition of rejected product must be documented, and identified problems corrected to prevent recurrence. A failed specification is therefore not simply an unavailable appointment that can be rescheduled.

Planning practice — use an escalation message that states the batch or proposed run, blocked activity, current evidence, earliest supportable next step, affected dispatch request and decision owner. Include the next update time if the resolution time remains unknown. This is more useful than announcing a new departure time while leaving QC or review capacity unconfirmed.

Review alternatives explicitly: keep the later window, rearrange other confirmed work, assess another suitable resource, defer the run or cancel it. Record which option was selected and why. A cancellation should trigger deliberate treatment of material reservations, unused labels, retained records and outstanding communications; it should not silently delete the planning history or count reserved stock as consumed.

Law — § 212.80 requires suitable labeling and packaging that protect the product under established shipping, distribution, handling and use conditions. Labels must remain legible and affixed, label information must also be in the batch production record, and operations must prevent labeling and product mix-ups. Under § 212.90(a), written distribution procedures must ensure the chosen shipping method does not adversely affect identity, purity or quality. These are not transport-qualification instructions.

Planning practice — prepare the handover packet before the dispatch window, but distinguish prepared documents from verified actual events. Match the product and batch, applicable decision, label information, shipment quantity and destination. A completed packing task does not establish that the shipment has left, and a planned carrier appointment is not the actual shipment time.

Law — § 212.1 expressly excludes a common or contract carrier from the definition of receiving facility. Keep the carrier contact and receiving-facility contact distinct. Planning practice is to maintain a receiver list linked to each shipment, including multiple destinations where applicable, so a later result does not leave staff reconstructing recipients from a courier booking or an outdated request.

Law — § 212.60(g) requires complete laboratory test records, including sample identification, methods and calculations, data with test dates and times, identified instrument outputs, comparisons with acceptance criteria, and the tester’s initials or signature and test date. The calendar is an index into this evidence, not a replacement for the laboratory record.

Under § 212.110, Part 212 records must be maintained at the production facility or another reasonably accessible location, remain legible and protected against deterioration or loss, and be readily available for FDA review and copying. Records and documentation referenced in Part 212 must be retained for at least one year from final release, including conditional final release. The retention anchor is not the scheduled production start or carrier appointment.

Planning practice — close out the day with three reconciliations: material reservations against actual consumption, planned milestones against actual events, and open quality work against named owners and receiving facilities. Explain material variances and schedule changes without overwriting earlier entries. Distinguish the required Part 212 record set from optional planning aids in the site’s records arrangements.

• Can the next shift identify which runs were produced, held, rejected, authorized or shipped without inferring one state from another?
• Do accepted physical quantities reconcile with commitments, held reservations, free stock and actual consumption?
• Can a reviewer find the approved master, batch record, equipment evidence, laboratory record and authorization from the shipment identifier?
• Does every pending post-release result have an owner and a route to all actual receiving facilities where notification is required?

The readiness outcome is an honest decision: the proposed run fits the applicable controls and confirmed resources, it needs a revised window, or it cannot proceed as proposed. A useful plan makes that distinction early. Continue through the radiopharmaceutical resources for related reading; do not mistake a polished calendar for completed manufacturing evidence.